Bayer, Natco cancer, generics news
Bayer said it is pursuing in the Mumbai High Court a case against Natco's compulsory license in India to manufacture and market a generic version of Bayer's Nexavar sorafenib for kidney and liver cancer. The court is a level below India's Supreme Court. The pharma declined to disclose details, and Natco could not be reached.
In March, India's Intellectual Property Appellate Board (IPAB) upheld a 2012 decision granting Natco the compulsory license. Bayer was appealing the license, which the Indian Patent Office granted last March because Bayer did not make Nexavar available to the public at a "reasonably affordable price." In September, IPAB rejected a petition from Bayer for a stay of the order granting the compulsory license while the appeal was pending (see BioCentury, March 19, 2012; Sept. 24, 2012 & March 5, 2013). ...